skip to main content

About Us

Gene Therapies to Slow or Stop the Neurodegenerative Process

At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.

Prevail was founded in a collaborative effort by Asa Abeliovich, M.D., Ph.D., OrbiMed and The Silverstein Foundation for Parkinson’s with GBA, who shared a common vision: to eradicate Parkinson’s disease and related disorders. We are developing our AAV9-based gene therapies for genetically defined patient populations, which we believe will increase the probability of creating disease-modifying therapies that improve patient outcomes.

Prevail was launched in 2017 with a world-class leadership team, partners and investors. We are headquartered in New York City at the Alexandria Center for Life Science. In 2021 Prevail Therapeutics was acquired by Eli Lilly and Company, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the website.

You are now leaving

You've clicked on a link for a third-party site, which Prevail Therapeutics does not control, influence, or endorse. Prevail is not responsible for any content on this third-party site, including the privacy policy. Click "Continue" to leave or "Go Back" to return to